AR043793A1 - Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana - Google Patents

Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana

Info

Publication number
AR043793A1
AR043793A1 ARP040101065A ARP040101065A AR043793A1 AR 043793 A1 AR043793 A1 AR 043793A1 AR P040101065 A ARP040101065 A AR P040101065A AR P040101065 A ARP040101065 A AR P040101065A AR 043793 A1 AR043793 A1 AR 043793A1
Authority
AR
Argentina
Prior art keywords
piperidin
piperazine
hydrochloride
treatment
tirosil
Prior art date
Application number
ARP040101065A
Other languages
English (en)
Inventor
Henri Doods
Klaus Rudolf
Wolfgang Eberlein
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR043793A1 publication Critical patent/AR043793A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procedimiento para el tratamiento o la prevención de dolores de cabeza, migrana o cefalea acumulada, en el que el procedimiento comprende la administración común de una cantidad terapéuticamente eficaz del hidrocloruro de la base del principio activo 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihidro-2(1H)-oxo-quinazolin-3-il)-1-piperidinil]-carbonil]-D-tirosil]-L-lisil]-4-(4-piperidin)-piperazina (a) y una cantidad terapéuticamente eficaz del principio activo contra la migrana sumatriptano, o una de las sales fisiológicamente aceptables del mismo; así como la correspondiente composición farmacéutica y su producción.
ARP040101065A 2003-04-01 2004-03-31 Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana AR043793A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10314617A DE10314617A1 (de) 2003-04-01 2003-04-01 Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne

Publications (1)

Publication Number Publication Date
AR043793A1 true AR043793A1 (es) 2005-08-10

Family

ID=32980861

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101065A AR043793A1 (es) 2003-04-01 2004-03-31 Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana

Country Status (9)

Country Link
EP (1) EP1631282A1 (es)
JP (1) JP2006522044A (es)
AR (1) AR043793A1 (es)
CA (1) CA2520930A1 (es)
CL (1) CL2004000686A1 (es)
DE (1) DE10314617A1 (es)
TW (1) TW200501956A (es)
UY (1) UY28251A1 (es)
WO (1) WO2004087134A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102322A1 (de) * 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
US20110212980A1 (en) * 2008-10-22 2011-09-01 Novartis Ag Combinations for the treatment of migraine
EP3416618A1 (en) 2016-02-19 2018-12-26 ZP Opco, Inc. Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
US11660264B2 (en) 2017-08-23 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
US11660265B2 (en) 2018-06-28 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096

Also Published As

Publication number Publication date
JP2006522044A (ja) 2006-09-28
TW200501956A (en) 2005-01-16
DE10314617A1 (de) 2004-10-14
EP1631282A1 (de) 2006-03-08
CL2004000686A1 (es) 2005-02-04
WO2004087134A1 (de) 2004-10-14
UY28251A1 (es) 2004-11-08
CA2520930A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
ECSP066327A (es) Composición de fexofenadina y proceso para prepararla
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
PE20120252A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
BRPI0315315B8 (es)
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
AR036265A1 (es) Uso de bibn4096 en combinacion con otros farmacos antimigranosos para el tratamiento de migrana
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
IL178591A (en) 4– (Amino) –2– (2,6 – Dioxo (3-piperidyl)) - Isoindulin – 1,3 – Dion for the treatment and management of myelodysplastic syndromes
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
PE20211818A1 (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR038571A1 (es) Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096
AR031679A1 (es) Una composicion farmaceutica
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
AR043793A1 (es) Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana
MXPA06003122A (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient

Legal Events

Date Code Title Description
FB Suspension of granting procedure